Tower Research Capital LLC TRC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 208.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 201,060 shares of the biopharmaceutical company’s stock after acquiring an additional 135,782 shares during the quarter. Tower […]
Tower Research Capital LLC TRC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 208.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 201,060 shares of the biopharmaceutical company’s stock after acquiring an additional 135,782 shares during the quarter. Tower […]
Premier Fund Managers Ltd lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 9,864 shares of the biopharmaceutical company’s stock after selling 800 shares during the quarter. Premier Fund Managers Ltd’s holdings in Gilead Sciences […]
Provident Investment Management Inc. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 8.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,000 shares of the biopharmaceutical company’s stock after selling 1,338 shares during […]
Paradigm Asset Management Co. LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 24,000 shares of the biopharmaceutical company’s stock after selling 700 shares during the quarter. Paradigm Asset Management Co. LLC’s holdings in Gilead Sciences were worth $1,944,000 […]